Mark Sullivan Biography

Mark Sullivan worked in drug development at Gilead Sciences in California and as chief operating officer of Australia's vaccine design and development consortium at the University of New South Wales. He has contributed to three successful global registrational programs for HIV and hepatitis B therapeutics has worked on 40 small molecule and biologic development programs at all stages and led the development of moxidectin through FDA approval. In 2005 he founded not-for-profit Medicines Development for Global Health to bring industry expertise and much-needed funding to the development of neglected diseases affecting mostly people in the developing world. Sullivan secured funding for the work based on the potential value of auctioning off a transferable Priority Review voucher which the FDA gives to developers of drugs for neglected tropical diseases and can cut approval time for a new drug from 10 months to 6 months an advantage for which drugmakers have recently paid over $100 million. With the proceeds from the pending auction Sullivan aims to expand MDGH's portfolio and prove a model for neglected disease research that doesn't require being an organization with our hand out for donations.

As a renowned expert and highly sought-after speaker, Mark Sullivan's expertise is in high demand. To book Mark Sullivan for your next event, conference, or workshop, please contact our speaker booking agency. Our experienced team will work closely with you to understand your specific needs and help secure Mark Sullivan's participation. With our professional guidance and seamless booking process, you can ensure a memorable and impactful experience for your audience. Don't miss the opportunity to engage your audience with Mark Sullivan's compelling insights and inspire positive change within your organization. Fill out the booking request form to take the first step in securing Mark Sullivan for your next speaking engagement.